YD Bio Limited (YDES)
NASDAQ:YDES
Top Page
YD Bio Limited
(NASDAQ:YDES)
Select Model
Select Model
Rating:47Neutral
Price Target:
$11.50
Action:ReiteratedDate:01/07/26
The score is driven primarily by weak financial performance (losses, negative margins, and negative operating/free cash flow), partially offset by low balance-sheet leverage. Technical indicators add downside pressure with the price below key moving averages and a negative MACD, while valuation provides limited support due to loss-making earnings and no dividend.
Positive Factors
Low leverage / strong equity base
Extremely low leverage reduces solvency and refinancing risk, giving management durable financial flexibility to fund R&D, clinical programs, or M&A without immediate debt pressure. This supports multi‑year development timelines common in biotech.
Negative Factors
Declining gross margin and negative profitability
Sustained margin deterioration erodes core earnings power and means the company must generate materially higher revenue to reach breakeven. Negative EBIT/EBITDA indicate operations are not yet self‑supporting, raising reliance on external funding over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong equity base
Extremely low leverage reduces solvency and refinancing risk, giving management durable financial flexibility to fund R&D, clinical programs, or M&A without immediate debt pressure. This supports multi‑year development timelines common in biotech.
Read all positive factors
YD Bio Limited (YDES) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$441.46M
Dividend YieldN/A
Average Volume (3M)91.42K
Price to Earnings (P/E)―
Beta (1Y)0.52
Revenue GrowthN/A
EPS Growth14.61%
CountryUS
Employees4
SectorFinancial
Sector Strength70
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding70,521,360
10 Day Avg. Volume96,756
30 Day Avg. Volume91,419
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)7.57
Price to Sales (P/S)97.81
P/FCF Ratio-10.51
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-147.81
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
YD Bio Limited Business Overview & Revenue Model
Company Description
Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases...
How the Company Makes Money
YD Bio Limited generates revenue through multiple channels, primarily by commercializing its therapeutic and diagnostic products. The company earns money by selling its FDA-approved drugs and diagnostic kits to healthcare providers, hospitals, and...
YD Bio Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 510.36K | 350.13K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 155.36K | 153.44K | 0.00 | 0.00 | 0.00 |
| EBITDA | -2.99M | -1.28M | 22.25K | 3.79M | 8.70M | -2.54M |
| Net Income | -2.97M | -1.41M | 13.56K | 3.79M | 8.70M | -2.54M |
Balance Sheet | ||||||
| Total Assets | 2.95M | 6.86M | 321.21K | 17.93M | 118.06M | 117.59M |
| Cash, Cash Equivalents and Short-Term Investments | 6.31K | 3.13M | 87.10K | 14.13K | 5.40K | 693.82K |
| Total Debt | 0.00 | 22.55K | 47.58K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 19.00M | 273.98K | 298.22K | 6.74M | 9.11M | 17.81M |
| Stockholders Equity | -16.05M | 6.59M | 22.99K | 11.20M | 108.96M | 99.78M |
Cash Flow | ||||||
| Free Cash Flow | -1.18M | -4.75M | -55.95K | -3.02M | -688.42K | -253.62K |
| Operating Cash Flow | -1.18M | -1.84M | -55.66K | -3.02M | -688.41K | -253.63K |
| Investing Cash Flow | 7.95M | -2.90M | -290.00 | 100.38M | -1.15M | -116.72M |
| Financing Cash Flow | -6.81M | 7.73M | 113.89K | -97.34M | 1.15M | 117.67M |
YD Bio Limited Technical Analysis
―
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For YDES, the sentiment is undefined. The current price of undefined is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for YDES.
YD Bio Limited Peers Comparison
UnderperformOutperform
Sector (68)
YDES
YD Bio Limited
6.26
-5.12
-44.97%
SCNI
Scinai Immunotherapeutics
0.58
-1.42
-71.00%
ADTX
Aditxt
0.50
-2,259.50
-99.98%
SPRC
SciSparc Ltd.
3.15
-53.98
-94.49%
CDT
CDT Equity
4.08
-2,600.22
-99.84%
VRAX
Virax Biolabs Group Ltd. Class A
0.10
-0.92
-89.80%
YD Bio Limited Corporate Events
YD Bio Signs Binding LOI to Acquire Taiwan Immunotherapy Firm SSMC
Jan 30, 2026
On January 20, 2026, YD Bio Limited entered into a binding letter of intent to acquire all shares, assets and business of Taiwan-based Safe Save Medical Cell Sciences Technology Co., Ltd. via a newly formed offshore holding company, in a transact...
YD Bio Regains Nasdaq Audit Committee Compliance After Board Committee Changes
Jan 21, 2026
On January 16, 2026, YD Bio Limited’s board appointed Dr. Chang as chairman of the Compensation Committee and member of the Audit and Nominating and Corporate Governance Committees, and Dr. Lu as chairman of the Nominating and Corporate Gove...
YD Bio Overhauls Board After Majority Shareholders Act
Jan 16, 2026
On January 16, 2026, YD Bio Limited disclosed that two majority shareholders, YD Biopharma Holding Limited and EG Biomed Limited, had delivered a written shareholder consent resulting in significant changes to the company’s board of director...
YD Bio Unveils January 2026 Investor Deck Detailing U.S.-Focused Biotech Platform Expansion
Jan 15, 2026
On January 15, 2026, YD Bio Limited released a new investor presentation outlining its ongoing strategic transformation into an integrated biotechnology platform, intended for use at investor conferences and meetings with investors and potential b...
YD Bio Limited Replaces ARK Pro With MaloneBailey as Independent Auditor
Jan 6, 2026
On December 24, 2025, YD Bio Limited’s audit committee dismissed ARK Pro CPA Co as the company’s independent registered public accounting firm and, effective the same day, appointed MaloneBailey, LLP as its new auditor for the fiscal ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.